FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079498177> ?p ?o ?g. }

• W2079498177 abstract "Purpose: Stereotactic body radiation therapy (SBRT) is increasingly utilized as primary treatment for clinically localized prostate cancer. Consensus regarding the appropriate patient-reported outcome (PRO) endpoints for clinical trials for early stage prostate cancer RT is lacking. To aid in trial design, this study presents PROs over 36 months following SBRT for clinically localized prostate cancer. Methods: 174 hormone-naïve patients were treated with 35-36.25 Gy SBRT in 5 fractions. Patients completed the EPIC-26 questionnaire at baseline and all follow-ups; the proportion of patients developing a clinically significant decline in each EPIC domain was determined. The minimally important difference (MID) was defined as a change of one-half SD from the baseline. Per RTOG 0938, we examined the percentage of patients who reported decline in EPIC urinary summary score of >2 points and EPIC bowel summary score of >5 points from baseline to one year. Results: 174 patients received SBRT with minimum follow-up of 36 months. The proportion of patients reporting a clinically significant decline in EPIC urinary/bowel scores was 34%/30%, 40%/32.2%, and 32.8%/21.5% at 6, 12, and 36 months. The percentage of patients reporting decline in the EPIC urinary summary score of >2 points was 43.2%, 51.6% and 41.8% at 6, 12, and 36 months. The percentage of patients reporting decline in EPIC bowel domain summary score of >5 points was 29.6% 29% and 22.4% at 6, 12, and 36 months. Conclusion: Our treatment protocol meets the RTOG 0938 criteria for advancing to a Phase III trial compared to conventionally fractionated RT. Between 12-36 months, the proportion of patients reporting decrease in both EPIC urinary and bowel scores declined, suggesting late improvement in these domains. Further investigation is needed to elucidate 1) which domains bear the greatest influence on post-treatment QOL, and 2) at what time point PRO endpoint(s) should be assessed." @default.
• W2079498177 created "2016-06-24" @default.
• W2079498177 creator A5004815486 @default.
• W2079498177 creator A5013566053 @default.
• W2079498177 creator A5037942654 @default.
• W2079498177 creator A5044668340 @default.
• W2079498177 creator A5053178430 @default.
• W2079498177 creator A5055224745 @default.
• W2079498177 creator A5056302482 @default.
• W2079498177 creator A5056324966 @default.
• W2079498177 creator A5059504028 @default.
• W2079498177 creator A5067138654 @default.
• W2079498177 creator A5071648735 @default.
• W2079498177 creator A5072141421 @default.
• W2079498177 creator A5083755194 @default.
• W2079498177 creator A5090264152 @default.
• W2079498177 date "2015-03-31" @default.
• W2079498177 modified "2023-10-14" @default.
• W2079498177 title "Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?" @default.
• W2079498177 cites W1494104030 @default.
• W2079498177 cites W1516952155 @default.
• W2079498177 cites W1563830423 @default.
• W2079498177 cites W1977733462 @default.
• W2079498177 cites W1983129876 @default.
• W2079498177 cites W1989268854 @default.
• W2079498177 cites W2000657166 @default.
• W2079498177 cites W2011834196 @default.
• W2079498177 cites W2017622807 @default.
• W2079498177 cites W2022826257 @default.
• W2079498177 cites W2023314525 @default.
• W2079498177 cites W2043517595 @default.
• W2079498177 cites W2070309415 @default.
• W2079498177 cites W2076249131 @default.
• W2079498177 cites W2077234964 @default.
• W2079498177 cites W2078121754 @default.
• W2079498177 cites W2081342344 @default.
• W2079498177 cites W2083321519 @default.
• W2079498177 cites W2093212053 @default.
• W2079498177 cites W2094442174 @default.
• W2079498177 cites W2099716808 @default.
• W2079498177 cites W2101001966 @default.
• W2079498177 cites W2104242558 @default.
• W2079498177 cites W2108134400 @default.
• W2079498177 cites W2108903661 @default.
• W2079498177 cites W2117792530 @default.
• W2079498177 cites W2118638289 @default.
• W2079498177 cites W2124594281 @default.
• W2079498177 cites W2137282952 @default.
• W2079498177 cites W2140203312 @default.
• W2079498177 cites W2164748078 @default.
• W2079498177 cites W2171127338 @default.
• W2079498177 cites W2033728406 @default.
• W2079498177 doi "https://doi.org/10.3389/fonc.2015.00077" @default.
• W2079498177 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4379875" @default.
• W2079498177 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25874188" @default.
• W2079498177 hasPublicationYear "2015" @default.
• W2079498177 type Work @default.
• W2079498177 sameAs 2079498177 @default.
• W2079498177 citedByCount "11" @default.
• W2079498177 countsByYear W20794981772015 @default.
• W2079498177 countsByYear W20794981772016 @default.
• W2079498177 countsByYear W20794981772017 @default.
• W2079498177 countsByYear W20794981772018 @default.
• W2079498177 countsByYear W20794981772019 @default.
• W2079498177 countsByYear W20794981772020 @default.
• W2079498177 countsByYear W20794981772022 @default.
• W2079498177 crossrefType "journal-article" @default.
• W2079498177 hasAuthorship W2079498177A5004815486 @default.
• W2079498177 hasAuthorship W2079498177A5013566053 @default.
• W2079498177 hasAuthorship W2079498177A5037942654 @default.
• W2079498177 hasAuthorship W2079498177A5044668340 @default.
• W2079498177 hasAuthorship W2079498177A5053178430 @default.
• W2079498177 hasAuthorship W2079498177A5055224745 @default.
• W2079498177 hasAuthorship W2079498177A5056302482 @default.
• W2079498177 hasAuthorship W2079498177A5056324966 @default.
• W2079498177 hasAuthorship W2079498177A5059504028 @default.
• W2079498177 hasAuthorship W2079498177A5067138654 @default.
• W2079498177 hasAuthorship W2079498177A5071648735 @default.
• W2079498177 hasAuthorship W2079498177A5072141421 @default.
• W2079498177 hasAuthorship W2079498177A5083755194 @default.
• W2079498177 hasAuthorship W2079498177A5090264152 @default.
• W2079498177 hasBestOaLocation W20794981771 @default.
• W2079498177 hasConcept C115519274 @default.
• W2079498177 hasConcept C121608353 @default.
• W2079498177 hasConcept C124952713 @default.
• W2079498177 hasConcept C126322002 @default.
• W2079498177 hasConcept C126894567 @default.
• W2079498177 hasConcept C142362112 @default.
• W2079498177 hasConcept C203092338 @default.
• W2079498177 hasConcept C2776235491 @default.
• W2079498177 hasConcept C2780192828 @default.
• W2079498177 hasConcept C509974204 @default.
• W2079498177 hasConcept C535046627 @default.
• W2079498177 hasConcept C71924100 @default.
• W2079498177 hasConcept C77411442 @default.
• W2079498177 hasConceptScore W2079498177C115519274 @default.
• W2079498177 hasConceptScore W2079498177C121608353 @default.
• W2079498177 hasConceptScore W2079498177C124952713 @default.
• W2079498177 hasConceptScore W2079498177C126322002 @default.
• W2079498177 hasConceptScore W2079498177C126894567 @default.

• next